XFOR Stock Analysis: Buy, Sell, or Hold?
XFOR - X4 Pharmaceuticals, Inc. Common Stock
$4.03
0.05 (1.13%)
▲
5d:
+2.16%
30d:
-2.54%
90d:
-3.94%
BUY
MODERATE Confidence
Analysis Updated: Jul 31, 2026 12:00 AM ET
Earnings: Aug 14, 2026
10d
Get Alerted When XFOR Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: XFOR shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: XFOR shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: XFOR is currently trading at $4.03, which is considered fair relative to its 30-day fair value range of $3.79 to $4.20.
Technical Outlook: Technically, XFOR is showing sideways momentum. Immediate support is located at $3.56, while resistance sits at $4.23.
Market Sentiment: XFOR has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Implied Volatility is high (100th percentile), indicating expensive options premiums. This environment often favors selling options or covered calls to generate income. Wall Street analysts see significant upside, with an average price target of $11.60 (+191.5%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, XFOR is showing sideways momentum. Immediate support is located at $3.56, while resistance sits at $4.23.
Market Sentiment: XFOR has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Implied Volatility is high (100th percentile), indicating expensive options premiums. This environment often favors selling options or covered calls to generate income. Wall Street analysts see significant upside, with an average price target of $11.60 (+191.5%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$3.79 -
$4.20
Company Quality Score
54/100
(HOLD)
Options IV Signal
100th percentile
(EVENT RISK)
Volume Confirmation
HIGH
Confidence Score
68.8%
All Signals
- NEUTRAL: Price in fair range
- BEARISH: Options expensive (IV 100th percentile)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 191.5% below Wall St target ($11.60)
Trading Range Analysis
30-Day Trading Range
$3.79 -
$4.20
Current vs Trading Range
FAIR
Expected Move (7 Days)
±$2.28
(56.7%)
Support & Resistance Levels
Support Level
$3.56
Resistance Level
$4.23
Current Trend
Sideways
Technical data as of
Aug 3, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-4.85
Wall Street Target
$11.60
(+191.5%)
Revenue Growth (YoY)
-90.6%
Share & Embed Analysis
Last updated: August 03, 2026 2:23 PM ET
Data refreshes hourly during market hours. Next update: 3:23 PM
Data refreshes hourly during market hours. Next update: 3:23 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is XFOR showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$416 | 53 HOLD |
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
30 analysts |
$386 | 43 HOLD |
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$557 | 49 HOLD |
|
ASND
Ascendis Pharma AS |
STRONG BUY
16 analysts |
$309 | 54 HOLD |
|
APLS
Apellis Pharmaceuticals … |
BUY
22 analysts |
$41 | 59 HOLD |
